Experienced in X-Linked Hypophosphatemia

Dr. Roshanak Monzavi

Pediatric Endocrinology
4650 W Sunset Blvd, 
Los Angeles, CA 
Experienced in X-Linked Hypophosphatemia
4650 W Sunset Blvd, 
Los Angeles, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Roshanak Monzavi is a Pediatric Endocrinologist in Los Angeles, California. Dr. Monzavi is rated as an Experienced provider by MediFind in the treatment of X-Linked Hypophosphatemia. Her top areas of expertise are Type 1 Diabetes (T1D), Short Stature (Growth Disorders), Idiopathic Short Stature (ISS), and Familial Short Stature (FSS).

Her clinical research consists of co-authoring 18 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of X-Linked Hypophosphatemia.

Specialties
Pediatric Endocrinology
Licenses
Pediatric Endocrinology in CA
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

LA Care
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
View 5 Less Insurance Carriers -

Locations

4650 W Sunset Blvd, Los Angeles, CA 90027

Additional Areas of Focus

Dr. Monzavi has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

INHALE-1: A 26-week Primary Treatment Phase, With 26-week Extension, Open-label, Randomized Clinical Trial Evaluating the Efficacy and Safety of Afrezza® Versus Rapid-acting Insulin Analog Injections, Both in Combination With a Basal Insulin, in Pediatric Subjects With Type 1 or Type 2 Diabetes Mellitus
INHALE-1: A 26-week Primary Treatment Phase, With 26-week Extension, Open-label, Randomized Clinical Trial Evaluating the Efficacy and Safety of Afrezza® Versus Rapid-acting Insulin Analog Injections, Both in Combination With a Basal Insulin, in Pediatric Subjects With Type 1 or Type 2 Diabetes Mellitus
Enrollment Status: Completed
Publish Date: May 06, 2025
Intervention Type: Biological
Study Drugs: Afrezza, Rapid-acting Insulin Analog, Basal Insulin
Study Phase: Phase 3
An Open-Label, Multi-Center, Single-Dose Study to Assess the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Nasal Glucagon in Pediatric Patients With Type 1 Diabetes Aged 1 to <4 Years
An Open-Label, Multi-Center, Single-Dose Study to Assess the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Nasal Glucagon in Pediatric Patients With Type 1 Diabetes Aged 1 to <4 Years
Enrollment Status: Completed
Publish Date: May 23, 2024
Intervention Type: Drug
Study Drug: Glucagon
Study Phase: Phase 1
Hydroxychloroquine for Prevention of Abnormal Glucose Tolerance and Diabetes in Individuals At-risk for Type 1 Diabetes Mellitus (T1D)
Hydroxychloroquine for Prevention of Abnormal Glucose Tolerance and Diabetes in Individuals At-risk for Type 1 Diabetes Mellitus (T1D)
Enrollment Status: Terminated
Publish Date: April 09, 2024
Intervention Type: Drug
Study Drug: Hydroxychloroquine
Study Phase: Phase 2
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Humalog With an Open-Label Postprandial LY900014 Treatment Group in Children and Adolescents With Type 1 Diabetes
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Humalog With an Open-Label Postprandial LY900014 Treatment Group in Children and Adolescents With Type 1 Diabetes
Enrollment Status: Completed
Publish Date: January 24, 2022
Intervention Type: Drug
Study Drugs: LY900014, Insulin Lispro
Study Phase: Phase 3
A Prospective Randomized Placebo-Controlled Double Blind Clinical Trial to Evaluate the Safety and Efficacy of CLBS03 (Autologous Ex Vivo Expanded Polyclonal Regulatory T-cells) in Adolescents With Recent Onset Type 1 Diabetes Mellitus (T1DM)
A Prospective Randomized Placebo-Controlled Double Blind Clinical Trial to Evaluate the Safety and Efficacy of CLBS03 (Autologous Ex Vivo Expanded Polyclonal Regulatory T-cells) in Adolescents With Recent Onset Type 1 Diabetes Mellitus (T1DM)
Enrollment Status: Completed
Publish Date: January 08, 2021
Intervention Type: Biological
Study Phase: Phase 2
The Effects of Vitamin D Supplementation on Glycemic Control and Proinflammatory Markers Involved in Microvascular Complications in Adolescents With Type 1 Diabetes.
The Effects of Vitamin D Supplementation on Glycemic Control and Proinflammatory Markers Involved in Microvascular Complications in Adolescents With Type 1 Diabetes.
Enrollment Status: Completed
Publish Date: May 08, 2017
Intervention Type: Dietary supplement
Study Phase: Not Applicable
View 5 Less Clinical Trials

18 Total Publications

Type 2 Diabetes in a 4-Year-Old With Obesity: Considerations for Use of Semaglutide and Bariatric Surgery in Children.
Type 2 Diabetes in a 4-Year-Old With Obesity: Considerations for Use of Semaglutide and Bariatric Surgery in Children.
Journal: JCEM case reports
Published: March 28, 2025
Similar Doctors
Elite in X-Linked Hypophosphatemia
Dr. Pisit Pitukcheewanont
Pediatric Endocrinology
Elite in X-Linked Hypophosphatemia
Dr. Pisit Pitukcheewanont
Pediatric Endocrinology
4650 W Sunset Blvd, 
Los Angeles, CA 
 (0.1 miles away)
323-669-4606
Languages Spoken:
English

Pisit Pitukcheewanont is a Pediatric Endocrinologist in Los Angeles, California. Dr. Pitukcheewanont is rated as a Distinguished provider by MediFind in the treatment of X-Linked Hypophosphatemia. His top areas of expertise are X-Linked Hypophosphatemia, Malnutrition, Hypoparathyroidism-Intellectual Disability-Dysmorphism Syndrome, and Pediatric Growth Hormone Deficiency.

Experienced in X-Linked Hypophosphatemia
Dr. Ian L. Marpuri
Pediatric Endocrinology
Experienced in X-Linked Hypophosphatemia
Dr. Ian L. Marpuri
Pediatric Endocrinology
4650 West Sunset Boulevard, 
Los Angeles, CA 
 (0.1 miles away)
323-660-2450
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Ian Marpuri is a Pediatric Endocrinologist in Los Angeles, California. Dr. Marpuri is rated as an Advanced provider by MediFind in the treatment of X-Linked Hypophosphatemia. His top areas of expertise are Short Stature (Growth Disorders), Familial Short Stature (FSS), Idiopathic Short Stature (ISS), and Precocious Puberty. Dr. Marpuri is currently accepting new patients.

Experienced in X-Linked Hypophosphatemia
Dr. Daina Dreimane
Pediatric Endocrinology
Experienced in X-Linked Hypophosphatemia
Dr. Daina Dreimane
Pediatric Endocrinology
1201 West La Veta Avenue, 
Orange, CA 
 (32.7 miles away)
714-509-8634
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Daina Dreimane is a Pediatric Endocrinologist in Orange, California. Dr. Dreimane is rated as an Advanced provider by MediFind in the treatment of X-Linked Hypophosphatemia. Her top areas of expertise are Short Stature (Growth Disorders), Familial Short Stature (FSS), Idiopathic Short Stature (ISS), and Pediatric Growth Hormone Deficiency. Dr. Dreimane is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Monzavi's expertise for a condition
ConditionClose
      View All 22 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile